Spotlight – Travere trips up but others are following in rare kidney disease
Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.
Viridian aims to prove itself in thyroid eye
Forthcoming data will see the group take on Horizon, but subcutaneous projects could pose the real threat.
Spotlight – following Humira in hidradenitis suppurativa
Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.
Biopharma’s venture year ends with another dip
Last year saw plenty of cash deployed, but with sums shrinking each quarter the stage is set for further retrenchment.
Venture investors keep the purse strings tight
Third-quarter numbers show that biopharma venture investments are firmly back in 2018 territory.
In 2021 it paid to stay private when the chips were down
While biotech indices fell, 2021 saw private companies raise the largest amount of venture capital ever.
